Scott D. Newsome
Johns Hopkins University
OphthalmologyInternal medicineSurgeryPathologyMagnetic resonance imagingPhysical therapyPediatricsStiff person syndromeOptic neuritisTransverse myelitisMyelopathyMultiple sclerosisSpinal cordRetinalExpanded Disability Status ScaleNeuromyelitis opticaPeginterferon beta-1aIn patientMedicine
Publications 153
#1Patricia K. Coyle (SBU: Stony Brook University)H-Index: 42
#2Anne Gocke (Biogen Idec)H-Index: 1
Last. Scott D. Newsome (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 27
view all 4 authors...
#1Scott D. Newsome (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 27
#2Thomas F. Scott (Allegheny General Hospital)H-Index: 25
Last. Maria L. Naylor (Biogen Idec)H-Index: 4
view all 5 authors...
ABSTRACT null null Background null : Early intervention with well-tolerated disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) is recommended in order to delay disease progression, reduce neurologic damage, preserve brain volume, and optimize long-term patient outcomes. Lack of conversion of new/newly enlarging T2 (NET2) or gadolinium-enhancing (Gd+) lesions to chronic hypointensities (black hole conversion) and achievement of no evidence of disease activity (NE...
#1Yujie Wang (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 1
#2Mohammad Salehi Sadaghiani (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 10
Last. Scott D. Newsome (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 27
view all 6 authors...
Objective: To report clinical characteristics and fluorodeoxyglucose positron emission tomography (FDG-PET) findings in brain and muscle of individuals with Stiff Person Syndrome Spectrum Disorders (SPSSD). Methods: Retrospective cohort study from 1997-2018 at Johns Hopkins Hospital identified 170 individuals with SPS or Cerebellar Ataxia (CA) associated with anti-glutamic acid decarboxylase (GAD)-65 antibodies. Fifty-one underwent FDG-PET, with fifty involving the body and thirty with dedicated...
#1Lianrui Zuo (Johns Hopkins University)H-Index: 7
#2Blake E. Dewey (Johns Hopkins University)H-Index: 16
Last. Aaron Carass (Johns Hopkins University)H-Index: 33
view all 9 authors...
Abstract null null In magnetic resonance (MR) imaging, a lack of standardization in acquisition often causes pulse sequence-based contrast variations in MR images from site to site, which impedes consistent measurements in automatic analyses. In this paper, we propose an unsupervised MR image harmonization approach, CALAMITI (Contrast Anatomy Learning and Analysis for MR Intensity Translation and Integration), which aims to alleviate contrast variations in multi-site MR imaging. Designed using i...
#1Le H. Hua (Lou Ruvo Brain Institute)H-Index: 9
#2Ahmed Z. Obeidat (MCW: Medical College of Wisconsin)H-Index: 5
Last. Douglas JefferyH-Index: 26
view all 16 authors...
Abstract Management of multiple sclerosis and neuroimmunological disorders has become increasingly complex due to the expanding number of recognized neuroimmune disorders, increased number of therapeutic options, and multi-disciplinary care management needs of people with multiple sclerosis and neuroimmunological disorders. More subspecialists are needed to optimize care of these patients, and many fellowship programs have been created or expanded to increase the subspecialty workforce. Conseque...
#1Mike P. Wattjes (MHH: Hannover Medical School)H-Index: 63
#2Olga Ciccarelli (NIHR: National Institute for Health Research)H-Index: 73
Last. Claudio GasperiniH-Index: 58
view all 26 authors...
Summary null null The 2015 Magnetic Resonance Imaging in Multiple Sclerosis and 2016 Consortium of Multiple Sclerosis Centres guidelines on the use of MRI in diagnosis and monitoring of multiple sclerosis made an important step towards appropriate use of MRI in routine clinical practice. Since their promulgation, there have been substantial relevant advances in knowledge, including the 2017 revisions of the McDonald diagnostic criteria, renewed safety concerns regarding intravenous gadolinium-ba...
#1Patricia K. Coyle (SBU: Stony Brook University)H-Index: 42
#2Anne Gocke (Biogen Idec)H-Index: 1
Last. Scott D. Newsome (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 27
view all 4 authors...
People with multiple sclerosis (MS) are at risk for infections that can result in amplification of baseline symptoms and possibly trigger clinical relapses. Vaccination can prevent infection through the activation of humoral and cellular immune responses. This is particularly pertinent in the era of emerging novel vaccines against severe acute respiratory syndrome coronavirus 2, the virus that causes coronavirus disease 2019 (COVID-19). MS disease-modifying therapies (DMTs), which affect the imm...
#1Alexandra Simpson (Johns Hopkins University)H-Index: 4
#2Ellen M. Mowry (Johns Hopkins University)H-Index: 34
Last. Scott D. Newsome (Johns Hopkins University)H-Index: 27
view all 3 authors...
This review presents a comprehensive analysis of the current high-efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis (MS). We discuss the existing approved and emerging therapeutics in patients with relapsing and progressive forms of MS using data from clinical trials and observational studies. Treatment considerations in pediatric and pregnant populations are also reviewed. Finally, we discuss the treatment paradigms of the escalation and early aggressive ...
#1Kathryn C. Fitzgerald (Johns Hopkins University)H-Index: 25
#2Christopher A. Mecoli (Johns Hopkins University)H-Index: 10
Last. Michelle Petri (Johns Hopkins University)H-Index: 21
view all 34 authors...
Background People with autoimmune or inflammatory conditions taking immunomodulatory/suppressive medications may have higher risk of novel coronavirus disease 2019 (COVID-19). Chronic disease care has also changed for many patients, with uncertain downstream consequences. Methods We included participants with autoimmune or inflammatory conditions followed by specialists at Johns Hopkins. Participants completed periodic surveys querying comorbidities, disease-modifying medications, exposures, COV...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.